Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 4771
Gene Symbol: NF2
NF2
0.300 GeneticVariation disease UNIPROT
Entrez Id: 7009
Gene Symbol: TMBIM6
TMBIM6
0.200 ModifyingMutation disease RGD Identification of transmembrane proteins as potential prognostic markers and therapeutic targets in breast cancer by a screen for signal sequence encoding transcripts. 17054309 2006
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 Biomarker disease BEFREE Median age was 62 y (range, 31-90 y), most had ductal carcinoma (95%), and most were estrogen receptor-positive (97%). 30237211 2019
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 Biomarker disease BEFREE Here, we show that palbociclib, a CDK4/6 inhibitor, can inhibit both progression of ductal carcinoma <i>in situ</i> (DCIS) and growth of invasive disease in both an ER(-) basal breast cancer model (MCFDCIS) and an ER(+) luminal model (MCF7 intraductal injection). 31451564 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE This is a retrospective study in which FISH analysis of Her-2/Neu was carried out simultaneously on archived material of 50 cases previously diagnosed as invasive duct carcinoma and the corresponding nodal metastases from the Pathology Department, NCI. 29750667 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 GeneticVariation disease BEFREE We find enrichment in the Her2 subtype and ductal carcinoma among those observations exhibiting greater cluster correspondence across expression and CNA data. 31077301 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE A recently-developed dendritic cell-based vaccine against early breast cancer (ductal carcinoma in situ; DCIS) that generates strong Th1-dominated immunity against HER-2 has induced pathologic complete response in about one-third of immunized individuals. 30657766 2019
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 AlteredExpression disease BEFREE Furthermore, correlations between levels of these cytokines and the expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) in ductal carcinoma were determined. 29904427 2018
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE Furthermore, correlations between levels of these cytokines and the expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) in ductal carcinoma were determined. 29904427 2018
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE HER2-Positive Lobular Versus Ductal Carcinoma of the Breast: Pattern of First Recurrence and Molecular Insights. 29759595 2018
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE Patients enrolled were at premenopausal status and characterized by human epidermal growth factor receptor 2 (HER2)-negative, hormone-receptor positive (estrogen receptor/progesterone receptor-positive [ER/PR+]) or triple-negative (TNBC), LABC (T > 3 cm), with high-grade ductal carcinoma. 29744672 2018
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 Biomarker disease BEFREE The relationship between oestrogen receptor-alpha phosphorylation and the tumour microenvironment in patients with primary operable ductal breast cancer. 27891654 2017
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 AlteredExpression disease BEFREE The IMPC patients showed larger tumor size, more lymphatic invasion, higher expression levels of estrogen receptor (ER), increased Ki67 index, higher Jagged1 protein level, and denser infiltration of CD163+ macrophages compared to patients with invasive breast ductal carcinoma. 28422875 2017
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 AlteredExpression disease BEFREE Serum levels of IL-6 and IL-8 were significantly higher in the subjects with ductal carcinoma than in the controls, and strongly correlated with clinical tumor stage, lymph node metastasis, and ER and HER2 antigen expression (p < 0.05). 28791816 2017
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE Although molecular data suggest that atypical ductal hyperplasia (ADH) and duct carcinoma in situ (DCIS) are related lesions, albeit with vastly different clinical implications, the role of HER2/neu expression in atypical ductal hyperplasia is not well defined either. 27644608 2016
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE CD8(+) tumor-infiltrating lymphocytes contribute to spontaneous "healing" in HER2-positive ductal carcinoma in situ. 27061242 2016
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE As proof-of-concept we then applied the CLS test to two new cases of invasive synchronous bilateral breast cancer at our institution, each with one hormone receptor positive (ER+/PR+/HER2-) lobular and one triple negative ductal carcinoma. 26554380 2015
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE One patient (1 %) achieved a complete response (CR); eight (9 %), a partial response (PR) (includes breast (n = 7, one of which was HER2 2+ by IHC) and salivary ductal carcinoma (n = 1); and 14 (15 %), stable disease (SD) ≥6 months (total SD ≥ 6 months/PR/CR =23 (25 %). 25323060 2015
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE Histopathological analysis showed that the invasive primary tumor from which the MACL-1 cell line was derived, was a luminal A subtype carcinoma, while the ductal carcinoma in situ (DCIS) that gave rise to the MGSO-3 cell line was a HER2 subtype tumor, both showing different proliferation levels. 23404580 2013
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE ER/PR and HER2 status did not differ from that reported previously, showing a direct correlation to tumour type and grade of ductal carcinoma. 21668473 2011
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 Biomarker disease BEFREE Differential patterns of allelic loss in estrogen receptor-positive infiltrating lobular and ductal breast cancer. 18720524 2008
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE Whereas different molecular subtypes (luminal A, luminal B, basal, ERBB2-overexpressing, and normal-like) exist in DBCs, 95% MBCs display a basal profile, similar to that of basal DBCs. 16651414 2006
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 Biomarker disease BEFREE Our previous studies revealed that a subset of mammary ductal carcinoma in situ (DCIS) contained focally disrupted myoepithelial (ME) cell layers that were predominantly overlain by estrogen receptor (ER) negative cells, which showed a substantially higher rate of cell proliferation and genetic alterations than adjacent ER positive cells within the same duct. 15692763 2005
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 Biomarker disease BEFREE Novel estrogen receptor coactivator PELP1/MNAR gene and ERbeta expression in salivary duct adenocarcinoma: potential therapeutic targets. 16021574 2005
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.100 GeneticVariation disease BEFREE We found suggestions of an association between common haplotypes in ESR1 and the risk for ductal breast cancer that is stronger in heavy women. 15217512 2004